Drug Trial Radar · NCT06639087
A Phase Ib Study of AZD5462 on Top of Dapagliflozin in Participants With Heart Failure and Moderate Renal Impairment
Last checked: Nov 19, 2026Latest source record: Sep 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
8
Actual
Start
Sep 27, 2024
Primary completion
May 29, 2025
Study completion May 29, 2025
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- Collaborators
- Parexel
- First posted
- Oct 15, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A study to investigate the effects and safety of AZD5462 on top of dapagliflozin in participants with heart failure and moderate renal impairment.
Conditions
- Renal Impairment
- Heart Failure
Interventions
AZD5462Drug
Participants will receive AZD5462 on top of dapagliflozin once daily.
DapagliflozinDrug
Participants will receive dapagliflozin once daily with AZD5462 or placebo.
PlaceboOther
Participants will receive placebo on top of dapagliflozin once daily.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in sodium excretionTime frame: From Baseline to Day 1
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Research Site
Sofia, Bulgaria
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.